Skip to main content

Advertisement

SpringerLink
Log in

The UCA1/miR-204/Sirt1 axis modulates docetaxel sensitivity of prostate cancer cells

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

In this study, we firstly investigated the regulative effect of miR-204 on Sirt1 expression in prostate cancer cells. Then, we examined whether miR-204 downregulation in the cells is a result of UCA1 upregulation. In addition, the regulative effect of UCA1/miR-204/Sirt1 axis on docetaxel sensitivity of prostate cancer cells was studied.

Methods

QRT-PCR was performed to detect UCA1, miR-204 and Sirt1 mRNA expression. Western blot assay was performed to assess Sirt1, P-gp and caspase-3 expression. The regulative effect of UCA1/miR-204/Sirt1 axis on docetaxel sensitivity of prostate cancer cells was examined by measurement of docetaxel IC50, dictation of cleaved caspase-3 and flow cytometric analysis of cell apoptosis.

Results

MiR-204 negatively modulated Sirt1 expression in prostate cancer cells. UCA1 upregulation directly resulted in decreased miR-204 expression. UCA1 overexpression resulted in increased Sirt1 expression in PNT2 cells, while knockdown of endogenous UCA1 led to decreased Sirt1 in LNCaP and 22RV1 cells. UCA1 siRNA, Sirt1 siRNA and miR-204 mimics could enhance docetaxel-induced activation of caspase-3 and cell apoptosis in 22RV1/DR cells.

Conclusions

There is a UCA1/miR-204/Sirt1 axis in LNCaP and 22RV1 cells. The UCA1/miR-204/Sirt1 axis plays an important role in modulating in vitro docetaxel sensitivity of the prostate cancer cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Qiu MT, Hu JW, Yin R, Xu L (2013) Long noncoding RNA: an emerging paradigm of cancer research. Tumour Biol 34(2):613–620. doi:10.1007/s13277-013-0658-6

    Article  CAS  PubMed  Google Scholar 

  2. Zhang N, Yang GQ, Shao XM, Wei L (2016) GAS5 modulated autophagy is a mechanism modulating cisplatin sensitivity in NSCLC cells. Eur Rev Med Pharmacol Sci 20(11):2271–2277

    CAS  PubMed  Google Scholar 

  3. Zhang JH, Wei HW, Yang HG (2016) Long noncoding RNA SNHG15, a potential prognostic biomarker for hepatocellular carcinoma. Eur Rev Med Pharmacol Sci 20(9):1720–1724

    PubMed  Google Scholar 

  4. Wang XS, Zhang Z, Wang HC, Cai JL, Xu QW, Li MQ, Chen YC, Qian XP, Lu TJ, Yu LZ, Zhang Y, Xin DQ, Na YQ, Chen WF (2006) Rapid identification of UCA1 as a very sensitive and specific unique marker for human bladder carcinoma. Clin Cancer Res Official Journal of the American Association for Cancer Research 12(16):4851–4858. doi:10.1158/1078-0432.CCR-06-0134

    Article  CAS  Google Scholar 

  5. Tuo YL, Li XM, Luo J (2015) Long noncoding RNA UCA1 modulates breast cancer cell growth and apoptosis through decreasing tumor suppressive miR-143. Eur Rev Med Pharmacol Sci 19(18):3403–3411

    PubMed  Google Scholar 

  6. Xiao C, Wu CH, Hu HZ (2016) LncRNA UCA1 promotes epithelial-mesenchymal transition (EMT) of breast cancer cells via enhancing Wnt/beta-catenin signaling pathway. Eur Rev Med Pharmacol Sci 20(13):2819–2824

    CAS  PubMed  Google Scholar 

  7. Wang F, Ying HQ, He BS, Pan YQ, Deng QW, Sun HL, Chen J, Liu X, Wang SK (2015) Upregulated lncRNA-UCA1 contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK signaling pathway. Oncotarget 6(10):7899–7917. doi:10.18632/oncotarget.3219

    Article  PubMed  PubMed Central  Google Scholar 

  8. Wang F, Li X, Xie X, Zhao L, Chen W (2008) UCA1, a non-protein-coding RNA up-regulated in bladder carcinoma and embryo, influencing cell growth and promoting invasion. FEBS Lett 582(13):1919–1927. doi:10.1016/j.febslet.2008.05.012

    Article  CAS  PubMed  Google Scholar 

  9. Na XY, Liu ZY, Ren PP, Yu R, Shang XS (2015) Long non-coding RNA UCA1 contributes to the progression of prostate cancer and regulates proliferation through KLF4-KRT6/13 signaling pathway. Int J Clin Exp Med 8(8):12609–12616

    PubMed  PubMed Central  Google Scholar 

  10. Xue M, Pang H, Li X, Li H, Pan J, Chen W (2015) Long noncoding RNA UCA1 promotes bladder cancer cell migration and invasion via hsa-miR-145/ZEB1/2/FSCN1 pathway. Cancer Sci. doi:10.1111/cas.12844

    PubMed  PubMed Central  Google Scholar 

  11. Bian Z, Jin L, Zhang J, Yin Y, Quan C, Hu Y, Feng Y, Liu H, Fei B, Mao Y, Zhou L, Qi X, Huang S, Hua D, Xing C, Huang Z (2016) LncRNA-UCA1 enhances cell proliferation and 5-fluorouracil resistance in colorectal cancer by inhibiting miR-204-5p. Sci Rep 6:23892. doi:10.1038/srep23892

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Ding M, Lin B, Li T, Liu Y, Li Y, Zhou X, Miao M, Gu J, Pan H, Yang F, Li T, Liu XY, Li R (2015) A dual yet opposite growth-regulating function of miR-204 and its target XRN1 in prostate adenocarcinoma cells and neuroendocrine-like prostate cancer cells. Oncotarget 6(10):7686–7700

    Article  PubMed  PubMed Central  Google Scholar 

  13. Wilking MJ, Ahmad N (2015) The role of SIRT1 in cancer: the saga continues. Am J Pathol 185(1):26–28. doi:10.1016/j.ajpath.2014.10.002

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Yang X, Yang Y, Gan R, Zhao L, Li W, Zhou H, Wang X, Lu J, Meng QH (2014) Down-regulation of mir-221 and mir-222 restrain prostate cancer cell proliferation and migration that is partly mediated by activation of SIRT1. Plos One 9(6):e98833. doi:10.1371/journal.pone.0098833

    Article  PubMed  PubMed Central  Google Scholar 

  15. Lovaas JD, Zhu L, Chiao CY, Byles V, Faller DV, Dai Y (2013) SIRT1 enhances matrix metalloproteinase-2 expression and tumor cell invasion in prostate cancer cells. Prostate 73(5):522–530. doi:10.1002/pros.22592

    Article  CAS  PubMed  Google Scholar 

  16. Byles V, Zhu L, Lovaas JD, Chmilewski LK, Wang J, Faller DV, Dai Y (2012) SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis. Oncogene 31(43):4619–4629. doi:10.1038/onc.2011.612

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Moore RL, Faller DV (2013) SIRT1 represses estrogen-signaling, ligand-independent ERalpha-mediated transcription, and cell proliferation in estrogen-responsive breast cells. Journal Endocrinol 216(3):273–285. doi:10.1530/JOE-12-0102

    Article  CAS  Google Scholar 

  18. Kojima K, Ohhashi R, Fujita Y, Hamada N, Akao Y, Nozawa Y, Deguchi T, Ito M (2008) A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells. Biochem Biophys Res Commun 373(3):423–428. doi:10.1016/j.bbrc.2008.06.045

    Article  CAS  PubMed  Google Scholar 

  19. Biernacka KM, Uzoh CC, Zeng L, Persad RA, Bahl A, Gillatt D, Perks CM, Holly JM (2013) Hyperglycaemia-induced chemoresistance of prostate cancer cells due to IGFBP2. Endocr Relat Cancer 20(5):741–751. doi:10.1530/ERC-13-0077

    Article  CAS  PubMed  Google Scholar 

  20. Zhang L, Wang X, Chen P (2013) MiR-204 down regulates SIRT1 and reverts SIRT1-induced epithelial-mesenchymal transition, anoikis resistance and invasion in gastric cancer cells. BMC Cancer 13:290. doi:10.1186/1471-2407-13-290

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Shi Y, Huang J, Zhou J, Liu Y, Fu X, Li Y, Yin G, Wen J (2015) MicroRNA-204 inhibits proliferation, migration, invasion and epithelial-mesenchymal transition in osteosarcoma cells via targeting Sirtuin 1. Oncol Rep 34(1):399–406. doi:10.3892/or.2015.3986

    PubMed  Google Scholar 

  22. O’Neill AJ, Prencipe M, Dowling C, Fan Y, Mulrane L, Gallagher WM, O’Connor D, O’Connor R, Devery A, Corcoran C, Rani S, O’Driscoll L, Fitzpatrick JM, Watson RW (2011) Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. Mol Cancer 10:126. doi:10.1186/1476-4598-10-126

    Article  PubMed  PubMed Central  Google Scholar 

  23. Kerb R, Hoffmeyer S, Brinkmann U (2001) ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics 2(1):51–64. doi:10.1517/14622416.2.1.51

    Article  CAS  PubMed  Google Scholar 

  24. Ramalinga M, Roy A, Srivastava A, Bhattarai A, Harish V, Suy S, Collins S, Kumar D (2015) MicroRNA-212 negatively regulates starvation induced autophagy in prostate cancer cells by inhibiting SIRT1 and is a modulator of angiogenesis and cellular senescence. Oncotarget 6(33):34446–34457. doi:10.18632/oncotarget.5920

    PubMed  PubMed Central  Google Scholar 

  25. Kumar P, Sharad S, Petrovics G, Mohamed A, Dobi A, Sreenath TL, Srivastava S, Biswas R (2016) Loss of miR-449a in ERG-associated prostate cancer promotes the invasive phenotype by inducing SIRT1. Oncotarget. doi:10.18632/oncotarget.8061

    Google Scholar 

  26. Duan K, Ge YC, Zhang XP, Wu SY, Feng JS, Chen SL, Zhang LI, Yuan ZH, Fu CH (2015) miR-34a inhibits cell proliferation in prostate cancer by downregulation of SIRT1 expression. Oncol Lett 10(5):3223–3227. doi:10.3892/ol.2015.3645

    PubMed  PubMed Central  Google Scholar 

  27. Todorova K, Metodiev MV, Metodieva G, Zasheva D, Mincheff M, Hayrabedyan S (2016) miR-204 is dysregulated in metastatic prostate cancer in vitro. Mol Carcinog 55(2):131–147. doi:10.1002/mc.22263

    Article  CAS  PubMed  Google Scholar 

  28. Nie W, Ge HJ, Yang XQ, Sun X, Huang H, Tao X, Chen WS, Li B (2016) LncRNA-UCA1 exerts oncogenic functions in non-small cell lung cancer by targeting miR-193a-3p. Cancer Lett 371(1):99–106. doi:10.1016/j.canlet.2015.11.024

    Article  CAS  PubMed  Google Scholar 

  29. Fan Y, Shen B, Tan M, Mu X, Qin Y, Zhang F, Liu Y (2014) Long non-coding RNA UCA1 increases chemoresistance of bladder cancer cells by regulating Wnt signaling. FEBS J 281(7):1750–1758. doi:10.1111/febs.12737

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by National Natural Science Foundation (81570272, Bo YANG).

Author information

Authors and Affiliations

  1. The Department of Urology, Tianjin Institute of Urology, The 2nd Hospital of Tianjin Medical University, Tianjin Medical University, Tianjin, 300211, China

    Xu Wang & Baojing Ma

  2. Department of Cardiology, Chinese PLA General Hospital, No. 28 Fu-xing Road, Beijing, 100853, China

    Bo Yang

Authors
  1. Xu Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bo Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Baojing Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bo Yang.

Ethics declarations

Conflict of interest

The authors have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, X., Yang, B. & Ma, B. The UCA1/miR-204/Sirt1 axis modulates docetaxel sensitivity of prostate cancer cells. Cancer Chemother Pharmacol 78, 1025–1031 (2016). https://doi.org/10.1007/s00280-016-3158-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-016-3158-8

Keywords

Search

Navigation